Recently, Boston Scientific (BSX) received a notice from the Food and Drug Administration (FDA), whereby all the issues cited in the Company’s 2006 corporate warning letter have been resolved.

The warning letters from the FDA dates back to January 2006, when Boston Scientific was notified of the serious regulatory problems and corrective actions at three of its facilities. Following which the company took significant steps to identify the solutions for the quality issues and implement those. The FDA has subsequently lifted a number of corporate restrictions based on adequate resolution of the quality issues, but the corporate warning letter still remained awaiting FDA’s internal administrative procedures.

For Boston Scientifics’ implantable medical devices such as coronary stents and cardiac defibrillators, quality control is extremely important for the recipient patient. Patients and physicians have lost confidence in the quality and reliability of Boston’s products as they have been plagued by quality control issues. Thus, the FDA moratorium could have a major detrimental impact on the product development pipeline, thereby having an adverse impact on financial results. The long-awaited resolution of these corporate warning letters thus marks an important achievement for the company.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices for minimally invasive therapeutic procedures. The company’s success depends heavily on how well it maintains its market share in the face of increasingly tougher competition and its serious quality-control issues. It continues to invest in its strong development pipeline so as to compete in the next generation of medical devices.

The company participates in several markets Incorporatedluding CRM, Cardiovascular, Endosurgery and Neuromodulation, where it faces competition from several large companies, specifically Johnson & Johnson (JNJ), St. Jude (STJ), Medtronic (MDT), and Edwards Lifesciences (EW). We hope Boston Scientific will fully resolve its quality control issues and establish its strong foothold in the Medical device industry.

Zacks Investment Research

1. (BSX) Boston Scientific Earns FDA Approval for Menorrhagia TreatmentBoston Scientific Corporation (BSX) recently received U.S. Food and Drug Administration (FDA) approval for its...
2. (BSX) Boston Scientific Enters Deal With Bladder Health NetworkBoston Scientific Corp. (BSX) recently entered into a four-year exclusive marketing agreement with Bladder Health...
3. (BSX) Boston Scientific Earns FDA Approval on Two Manufacturing ChangesBoston Scientific Corporation (BSX) recently received the U.S. Food and Drug Administration (FDA) clearance for...
4. (BSX) Boston Scientific Faces Potential Class Action LawsuitBoston Scientific Corporation (BSX) recently faced legal action when law firm Izard Nobel LLP filed...
5. (BSX) Boston Scientific Suspends Sales of Defibrillators – Failed to Notify FDA of ChangesBoston Scientific Corporation (BSX) recently suspended sales of its defibrillators after the company failed to...
6. (BSX) Boston Scientific Settles Department of Justice InvestigationBoston Scientific Corp. (BSX) recently settled the U.S. Department of Justice (DOJ) investigation pertaining to...

Search Posts by Tag: Boston Scientific Corporation | BSX | Edwards Lifesciences Corporation | EW | JNJ | Johnson & Johnson | MDT | Medtronic Inc | St. Jude Medical Inc | STJ | Healthcare

RSS Feeds by Tag: Boston Scientific Corporation | BSX | Edwards Lifesciences Corporation | EW | JNJ | Johnson & Johnson | MDT | Medtronic Inc | St. Jude Medical Inc | STJ | Healthcare |

Other Posts by: vitalstocks | RSS Feed for this author